Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by pa...

This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel...

With this fully revised fourth edition, Dr Stahl returns to the essential roots of what it means to become a neurobiologically empowered psychopharmacologist, expertly guided in the selection and combination of treatments for individual patients in practice. Embracing the unifying themes of 'symptom endophenotypes', dimensions of psychopathology that cut across syndromes, and 'symptoms and circuits', every aspect of the text has been updated to the frontiers of current knowledge, with the ...

Dr Stahl's books occupy a central position as core educational resources in the psychopharmacology literature. Building on Dr Stahl's exceptional ability to communicate complex principles and make them easily understandable, this book offers 150 self-assessment questions derived from the Neuroscience Education Institute's Master Psychopharmacology Program. The self-assessment questions will help the reader to identify areas of competence or the need for further study and offers CME credit....

This volume presents up-to-date, comprehensive and high quality reviews of the psychopharmacological evidence-base for each of the major psychiatric disorders, written by expert psychopharmacologists from around the world. Building on the success of the first edition, the volume summarizes the wealth of new developments in the field and sets them within the context of day-to-day clinical practice. All chapters have been fully updated and new contributions on personality disorders and subst...

All of the titles in the Stahl's Illustrated series are designed to be fun. Concepts are illustrated by full-color images that will be familiar to all readers of Stahl's Essential Psychopharmacology, 3rd Edition and The Prescriber's Guide. The texts in this user-friendly series can be supplements to figures, images and tables. The visual learner will find that these books make psychopharmacology concepts easy to master, while the non-visual learner will enjoy a shortened text version of co...

The second book in the Evidence-Based Guides series, The Evidence-Based Guide to Antidepressant Medications, provides a clear reference to the current knowledge and evidence base for the use of antidepressants among a variety of patients across a wide range of disorders. Chapters within this guide are authored by experts in their respective areas of practice, and synthesize a large amount of medical literature into a comprehensive, yet understandable, concise, reader-friendly guide. Each c...

Treatment-resistant DepressSuccessful management of patients with treatment-resistant depression requires a thorough understanding of the biological basis for both the depression and its failure to respond to standard treatments. This book clearly and succinctly summarizes the latest scientific research and its applications in clinical practice.A first step is a clear definition of what constitutes treatment-resistant depression so that clinical trials and ...

The book highlights important new research using current state-of-the-art approaches by prominent researchers in the field of depression. A broad range of topics is covered, beginning with a description of the phenotypic features of clinical depression, followed by chapters on the cellular and molecular basis, functional neuroimaging correlates and information-processing accounts. Finally, existing and novel treatment approaches are covered. In this way the volume brings together the key d...

Translational neuroscience is at the heart of clinical advancement in the fields of psychiatry, neurology and neurodevelopmental disorders. Written and edited by leading scientists and clinicians, this is a comprehensive and authoritative analysis of this emerging strategy for developing more effective treatments for brain disorders. Introductory chapters bring together perspectives from both academia and industry, while subsequent sections focus on disease groups, including bipolar disord...

The World Health Organization defines depression as a primary contributor to the global burden of disease and predicts it will become the second leading cause of death by 2020. The need to develop effective therapies has never been so pressing. Current antidepressant drugs have several limitations. This 2010 book looks at the future of mood-disorder research, covering the identification of new therapeutic targets, establishing new preclinical models, new medicinal chemistry opportunities, ...

Antipsychotic Long-acting Injections (LAIs) were introduced in the 1960s to improve treatment adherence in schizophrenia. Subsequently, first-generation antipsychotic LAIs became widely used in many countries. Since the initial publication of Antipsychotic Long-acting Injections in 2010, new trial data have been published on long-acting injection (LAI) preparations of the drugs Risperidone, Paliperidone, and Olanzapine. Furthermore, a new LAI preparation of the drug Aripiprazole h...